What is he best known for?
The fields of study he is best known for:
- Immune system
- Gene
- Antibody
John T. Harty mostly deals with Cytotoxic T cell, Immunology, CD8, T cell and Antigen.
John T. Harty has researched Cytotoxic T cell in several fields, including Virology, Immune system, Immunity, Microbiology and Cell biology.
His Cell biology course of study focuses on Antigen-presenting cell and Priming.
His study on Effector, Vaccination, Proinflammatory cytokine and Adoptive cell transfer is often connected to Memory cell as part of broader study in Immunology.
The CD8 study combines topics in areas such as Epitope, Major histocompatibility complex, Cellular differentiation and Antigen presentation.
His research integrates issues of Blockade and Germinal center in his study of T cell.
His most cited work include:
- CD8+ T cell effector mechanisms in resistance to infection. (617 citations)
- Programmed contraction of CD8(+) T cells after infection. (541 citations)
- Shaping and reshaping CD8+ T-cell memory. (436 citations)
What are the main themes of his work throughout his whole career to date?
John T. Harty mainly focuses on Cytotoxic T cell, Immunology, CD8, T cell and Antigen.
His studies in Cytotoxic T cell integrate themes in fields like Epitope and Cell biology, Effector.
While the research belongs to areas of Cell biology, he spends his time largely on the problem of T-cell receptor, intersecting his research to questions surrounding Major histocompatibility complex.
His research brings together the fields of Virology and Immunology.
His studies deal with areas such as Molecular biology and Microbiology as well as CD8.
His Interleukin 21 research is multidisciplinary, relying on both Interleukin 12 and Cytolysis.
He most often published in these fields:
- Cytotoxic T cell (69.49%)
- Immunology (63.14%)
- CD8 (39.83%)
What were the highlights of his more recent work (between 2013-2021)?
- Cytotoxic T cell (69.49%)
- Immunology (63.14%)
- CD8 (39.83%)
In recent papers he was focusing on the following fields of study:
His primary areas of study are Cytotoxic T cell, Immunology, CD8, T cell and Antigen.
The various areas that John T. Harty examines in his Cytotoxic T cell study include Cell biology, Effector and Immune system.
His research investigates the connection between Cell biology and topics such as Transcription factor that intersect with problems in Epigenetics.
His CD8 study incorporates themes from Virus, Heterosubtypic immunity and Recombinant DNA.
His Antigen research incorporates elements of Demyelinating disease, Antigen presentation and In vivo.
John T. Harty works mostly in the field of Immunity, limiting it down to topics relating to Virology and, in certain cases, Epitope, Immunization and Antibody.
Between 2013 and 2021, his most popular works were:
- Dynamics of influenza-induced lung-resident memory T cells underlie waning heterosubtypic immunity (137 citations)
- Impact of Inflammatory Cytokines on Effector and Memory CD8+ T Cells (118 citations)
- IL-12 and type I interferon prolong the division of activated CD8 T cells by maintaining high-affinity IL-2 signaling in vivo (90 citations)
In his most recent research, the most cited papers focused on:
- Immune system
- Gene
- Antibody
His main research concerns Cytotoxic T cell, Immunology, T cell, CD8 and IL-2 receptor.
His Cytotoxic T cell research is multidisciplinary, incorporating elements of Heterosubtypic immunity, Malaria, Immune system, Virus and Cell biology.
He combines subjects such as Secondary infection and Sepsis with his study of Immune system.
His research in Antigen, Immunity, Effector, Cytokine and Plasmodium are components of Immunology.
His work on Interleukin 21 and CD1D as part of general T cell research is frequently linked to Chromatin immunoprecipitation, bridging the gap between disciplines.
His study looks at the intersection of Interleukin 21 and topics like Antigen-presenting cell with Memory T cell and CD28.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
